#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating older adults should understand that cannabis use in this population is primarily motivated by symptom management rather than recreational purposes, which may warrant reassessment of pain, sleep, and anxiety management strategies in their clinical approach. This evidence supports the need for open, non-judgmental conversations with older patients about cannabis use, as it may indicate inadequately treated symptoms that could benefit from conventional or complementary interventions. Understanding these motivations helps clinicians provide more comprehensive care while monitoring for drug interactions and safety concerns specific to aging populations.
# Clinical Summary
This report documents that older adults are increasingly using cannabis primarily for symptom management rather than recreational purposes, with perceived efficacy being a key driver of use in this population. The finding is clinically significant because older adults often experience multiple chronic conditions such as chronic pain, insomnia, and chemotherapy-related side effects where cannabis may offer symptom relief, yet evidence-based guidance for this age group remains limited. Understanding the symptom profiles and perceived benefits driving cannabis use in older patients can help clinicians engage in more informed discussions about alternative and complementary therapies during patient encounters. The shift toward symptom-focused use in geriatric populations underscores the need for additional research specifically in older adults to establish safety profiles, efficacy data, and appropriate dosing recommendations that account for age-related pharmacokinetic changes and polypharmacy concerns. Clinicians should document cannabis use as part of their medication history with older patients and consider having evidence-informed conversations about realistic expectations, potential drug interactions, and when cannabis might be appropriate relative to conventional treatments for their specific conditions.
“What I’m seeing in my practice aligns with this data: older patients are turning to cannabis not for recreational purposes but as a pragmatic tool for conditions like neuropathic pain, insomnia, and chemotherapy-related nausea where conventional options have failed or created intolerable side effects. The challenge is that we’re operating with a significant evidence gap, so I counsel patients carefully about dose, drug interactions, and fall risk while being honest that for some conditions, the clinical benefit they’re experiencing is real and measurable.”
? While the growing use of cannabis among older adults for symptom management reflects both patient-driven interest and potential treatment gaps, clinicians should recognize that evidence for efficacy in this population remains limited and heterogeneous across different conditions and cannabinoid formulations. Older adults may be particularly vulnerable to drug interactions, cognitive effects, and fall risk from cannabis, yet they are often underrepresented in clinical trials and may lack access to quality medical guidance about use. The self-reported perception of effectiveness does not necessarily align with rigorous efficacy data, and selection of cannabinoid type, dose, and route of administration is frequently made without standardized clinical protocols. As cannabis becomes more accessible, primary care and specialty providers should develop competency in discussing cannabis use with older patients, including explicit inquiry about current or contemplated use, while educating patients about gaps in evidence and potential harms specific to aging. Until more robust clinical research emerges in older populations, a
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
